Replies to Post #1103 onBristol Myers Squibb (BMY)

Replies to post #1103 on Bristol Myers Squibb (BMY)

Replies to #1103 on Bristol Myers Squibb (BMY)

09/10/22 2:53 PM

#1104 RE: DewDiligence #1103

Perfect timing—BMY reports 2yr Sotyktu data in psoriasis at EADV conference:

https://finance.yahoo.com/news/bristol-myers-squibb-announces-sotyktu-063000160.html

01/27/23 10:29 AM

#1125 RE: DewDiligence #1103

CHMP approves BMY’s Sotyktu for psoriasis:

https://www.businesswire.com/news/home/20230125005858/en

02/02/23 9:23 AM

#1128 RE: DewDiligence #1103

BMY’s Sotyktu patients are coming approximately 1/3 from treatment-naïve, 1/3 for Otezla switches, and 1/3 from biologic switches. (Source: 4Q22 CC.)

03/18/23 4:39 PM

#1137 RE: DewDiligence #1103

TAK-279 vs Sotyktu (from biopharmadive.com): #msg-171480207.

03/28/23 10:17 AM

#1138 RE: DewDiligence #1103

EC approves Sotyktu for psoriasis:

https://finance.yahoo.com/news/bristol-myers-squibb-receives-european-105900011.html

Essentially same label as FDA’s.